Zynex (ZYXI) Expected to Announce Quarterly Earnings on Monday

Zynex (NASDAQ:ZYXI) is expected to issue its Q4 2025 results after the market closes on Monday, April 27th. Analysts expect the company to announce earnings of ($0.15) per share and revenue of $22.60 million for the quarter. Parties can find conference call details on the company’s upcoming Q4 2025 earning report page for the latest details on the call scheduled for Thursday, April 9, 2026 at 4:00 PM ET.

Zynex Stock Performance

Shares of ZYXI opened at $0.13 on Friday. The company has a quick ratio of 0.32, a current ratio of 0.47 and a debt-to-equity ratio of 0.56. The business’s 50 day moving average price is $0.12 and its 200-day moving average price is $0.45. Zynex has a 52 week low of $0.12 and a 52 week high of $2.82. The stock has a market cap of $3.80 million, a P/E ratio of -0.05 and a beta of 0.99.

Institutional Trading of Zynex

A number of hedge funds have recently made changes to their positions in ZYXI. Goldman Sachs Group Inc. boosted its position in shares of Zynex by 118.2% in the 1st quarter. Goldman Sachs Group Inc. now owns 170,718 shares of the company’s stock worth $376,000 after purchasing an additional 92,463 shares in the last quarter. Jane Street Group LLC lifted its position in Zynex by 239.9% in the 1st quarter. Jane Street Group LLC now owns 53,377 shares of the company’s stock valued at $117,000 after acquiring an additional 37,673 shares in the last quarter. XTX Topco Ltd bought a new position in Zynex in the 2nd quarter valued at approximately $47,000. Marshall Wace LLP bought a new position in Zynex in the 2nd quarter valued at approximately $131,000. Finally, Bridgeway Capital Management LLC bought a new position in Zynex in the 2nd quarter valued at approximately $108,000. 29.68% of the stock is owned by institutional investors.

Zynex Company Profile

Zynex, Inc is a medical device company engaged in the design, development, manufacture and sale of non-invasive therapeutic and patient monitoring equipment in the United States. Headquartered in Englewood, Colorado, the company focuses on delivering FDA-cleared solutions aimed at pain management, neurological rehabilitation and remote patient monitoring. Zynex’s portfolio is structured to address the needs of healthcare providers, outpatient clinics and patients receiving care in their homes.

The company’s core product offerings include electrotherapy devices—such as transcutaneous electrical nerve stimulation (TENS) and neuromuscular electrical stimulation (NMES) systems—designed to alleviate pain and assist in muscle recovery.